Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$903M |
| 2 |
Charles Schwab
SCHW
|
$631M |
| 3 |
Affirm
AFRM
|
$556M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
$514M |
| 5 |
Coupang
CPNG
|
$458M |
Top Sells
| 1 |
Tesla
TSLA
|
$3.23B |
| 2 |
Full Truck Alliance
YMM
|
$995M |
| 3 |
ResMed
RMD
|
$718M |
| 4 |
NVIDIA
NVDA
|
$691M |
| 5 |
Amazon
AMZN
|
$509M |
Sector Composition
| 1 | Consumer Discretionary | 26.58% |
| 2 | Healthcare | 23.23% |
| 3 | Technology | 21.05% |
| 4 | Communication Services | 12.81% |
| 5 | Financials | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
American Superconductor
AMSC
$2.21B
| $16.2M | 0.01% |
1,491,370
| – | – |
|
|
TRHC
227
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $16.2M | 0.01% |
1,081,497
+31,998
| +3% | +$480K |
|
228
Align Technology
ALGN
$10.1B
| $16.2M | 0.01% |
24,631
| – | – |
|
|
SIX
229
DELISTED
Six Flags Entertainment Corp.
SIX
| $15.8M | 0.01% |
371,260
-14,441
| -4% | -$615K |
|
230
Health Catalyst
HCAT
$238M
| $15.8M | 0.01% |
398,379
+17,376
| +5% | +$688K |
|
231
Sherwin-Williams
SHW
$92.9B
| $15.7M | 0.01% |
44,453
| – | – |
|
232
FirstCash
FCFS
$6.53B
| $15.5M | 0.01% |
206,551
-8,036
| -4% | -$601K |
|
233
Royal Caribbean
RCL
$95.7B
| $13.9M | 0.01% |
180,957
-7,382
| -4% | -$568K |
|
234
Butterfly Network
BFLY
$393M
| $13.9M | 0.01% |
2,073,538
+58,530
| +3% | +$392K |
|
|
KDNY
235
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $13.8M | 0.01% |
843,812
+6,236
| +0.7% | +$102K |
|
236
Bumble
BMBL
$697M
| $13.5M | 0.01% |
400,000
| – | – |
|
237
XP
XP
$9.96B
| $13.4M | 0.01% |
+465,262
| New | +$13.4M |
|
238
Cooper Companies
COO
$13.5B
| $13.1M | 0.01% |
125,492
| – | – |
|
239
HUTCHMED
HCM
$2.74B
| $12.8M | 0.01% |
364,068
-3,897
| -1% | -$137K |
|
|
API
240
Agora
API
$310M
| $12.1M | 0.01% |
744,300
| – | – |
|
|
NBTX
241
Nanobiotix
NBTX
$419M
| $11.6M | 0.01% |
1,400,000
| – | – |
|
242
Ascendis Pharma
ASND
$12.5B
| $11.6M | 0.01% |
86,072
+2,638
| +3% | +$355K |
|
243
Verisk Analytics
VRSK
$37.8B
| $11.6M | 0.01% |
50,495
| – | – |
|
244
Visa
V
$666B
| $11.4M | 0.01% |
52,499
-11
| -0% | -$2.38K |
|
|
BNFT
245
DELISTED
Benefitfocus, Inc.
BNFT
| $10.8M | 0.01% |
1,013,175
+72,783
| +8% | +$776K |
|
246
Bilibili
BILI
$9.25B
| $10.3M | 0.01% |
222,825
-737,491
| -77% | -$34.2M |
|
247
Veeva Systems
VEEV
$44.7B
| $10.3M | 0.01% |
40,213
+1,742
| +5% | +$445K |
|
248
Ionis Pharmaceuticals
IONS
$9.76B
| $9.61M | 0.01% |
315,820
+13,817
| +5% | +$420K |
|
|
DCBO
249
Docebo
DCBO
$896M
| $9.39M | 0.01% |
139,693
+4,275
| +3% | +$287K |
|
|
CLLS
250
Cellectis
CLLS
$269M
| $8.77M | ﹤0.01% |
1,079,511
+2,986
| +0.3% | +$24.2K |
|